Table 3.
Distribution of use of OGLD in participants with type 2 diabetes between 2005 and 2017
| Characteristic | Wave 1 (2005) N = 9918 |
Wave 2 (2006) N = 17,232 |
Wave 3 (2008) N = 12,210 |
Wave 4 (2010) N = 5343 |
Wave 5 (2011–12) N = 9603 |
Wave 6 (2013–14) N = 5479 |
Wave 7 (2016–17) N = 6303 |
|---|---|---|---|---|---|---|---|
| Proportion of participants treated with OGLD, % | 81.0 | 84.9 | 87.1 | 91.8 | 85.6 | 87.0 | 88.4 |
| Number of OGLD treatments received | |||||||
| 1 OGLD therapy, n (%) | 3527 (35.7) | 6353 (36.9) | 4293 (36.0) | 2304 (43.6) | 4542 (47.3) | 1876 (34.2) | 2125 (34.6) |
| >1 OGLD therapy, n (%) | 4478 (45.3) | 8248 (47.9) | 6062 (50.8) | 2536 (48.0) | 3672 (38.2) | 2890 (52.8) | 3295 (53.6) |
| Type of OGLD treatment receiveda | |||||||
| Metformin alone, n (%) | – | 3258 (18.9) | 2517 (21.1) | 1246 (23.6) | 2342 (24.4) | 1459 (26.6) | 1638 (26.7) |
| Sulfonylureas alone, n (%) | – | 2371 (13.8) | 1331 (11.2) | 307 (5.8) | 714 (7.4) | 306 (5.6) | 257 (4.2) |
| Metformin + sulfonylureas, n (%) | – | 6478 (37.6) | 4726 (39.6) | 2195 (41.6) | 3749 (39.0) | 2199 (40.1) | 2281 (37.2) |
| Other, n (%)b | – | 2494 (14.5) | 1781 (14.9) | 1092 (20.7) | 1409 (14.7) | 802 (14.6) | 1223 (20.0) |
Percentages were calculated for patients with available data; these varied by each category/wave
aData not available for wave 1
bDetailed information on ‘Other’ therapies is available in ESM Table 4